Angiographic predictors of 2-year stent thrombosis in patients receiving drug-eluting stents: Insights from the ADAPT-DES study

Catheterization and Cardiovascular Interventions

Volumn 89, Issue 1, 2017, Pages 26-35

  Généreux, Philippe ^a,b,c   Redfors, Björn ^a,h   Witzenbichler, Bernhard ^d   Maehara, Akiko ^a,b   Yadav, Mayank ^a   Weisz, Giora ^a,b,e   Francese, Dominic P ^a   Parvataneni, Rupa ^a   Brener, Sorin J ^f   Mehran, Roxana ^a,g   Kirtane, Ajay J ^a,b   Stone, Gregg W ^a,b  

^a CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^b Department of Orthopaedic Surgery   (United States)

^c HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^d Helios Amper Klinikum   (Germany)

^e SHAARE ZEDEK MEDICAL CENTER   (Israel)

^f NEW YORK METHODIST HOSPITAL   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

drug eluting stent; percutaneous coronary intervention; stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ANTITHROMBOCYTIC AGENT;

ADULT; ARTICLE; CALCIFICATION; CONTROLLED STUDY; CORONARY ANGIOGRAPHY; CORONARY ARTERY THROMBOSIS; DISEASE SEVERITY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PREDICTION; PROSPECTIVE STUDY; SAPHENOUS VEIN GRAFT; STENT THROMBOSIS; ADVERSE EFFECTS; AGED; BLOOD; BLOOD CLOTTING PARAMETERS; CASE CONTROL STUDY; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DEVICES; DIAGNOSTIC IMAGING; DRUG EFFECTS; GERMANY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE ACTIVATION; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES;

AGED; CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84956652337     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.26409     Document Type: Article

References (41)

1. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: Evidence from a comprehensive network meta-analysis. Lancet 2012;379:1393–1402.
2. Cannon CP, Harrington RA, James S, et al., PLATelet inhibition and patient Outcomes Investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): A randomised double-blind study. Lancet 2010;375:283–293.
3. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): Double-blind, randomised controlled trial. Lancet 2009;373:723–731.
4. Kuchulakanti PK, Chu WW, Torguson R, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 2006;113:1108–1113.
5. Holmes DR Jr, Kereiakes DJ, Garg S, et al. Stent thrombosis. J Am Coll Cardiol 2010;56:1357–1365.
6. van Werkum JW, Heestermans AA, Zomer AC, et al. Predictors of coronary stent thrombosis: The Dutch Stent Thrombosis Registry. J Am Coll Cardiol 2009;53:1399–1409.
7. Kimura T, Morimoto T, Kozuma K, et al. Investigators R. Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: Observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART). Circulation 2010;122:52–61.
8. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. Jama 2005;293:2126–2130.
9. de la Torre-Hernandez JM, Alfonso F, Hernandez F, et al. Drug-eluting stent thrombosis: Results from the multicenter Spanish registry ESTROFA (Estudio ESpanol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol 2008;51:986–990.
10. Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356:1020–1029.
11. Roy P, Torguson R, Okabe T, et al. Angiographic and procedural correlates of stent thrombosis after intracoronary implantation of drug-eluting stents. J Interv Cardiol 2007;20:307–313.
12. Park DW, Park SW, Park KH, et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 2006;98:352–356.
13. Mishkel GJ, Moore AL, Markwell S, Shelton ME. Correlates of late and very late thrombosis of drug eluting stents. Am Heart J 2008;156:141–147.
14. Waksman R, Kirtane AJ, Torguson R, et al. Correlates and outcomes of late and very late drug-eluting stent thrombosis: Results from DESERT (International Drug-Eluting Stent Event Registry of Thrombosis). JACC Cardiovasc Interv 2014;7:1093–1102.
15. Stone GW, Witzenbichler B, Weisz G, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): A prospective multicentre registry study. Lancet 2013;382:614–623.
16. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007;115:2344–2351.
17. Machecourt J, Danchin N, Lablanche JM, et al. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: The EVASTENT Matched-Cohort Registry. J Am Coll Cardiol 2007;50:501–508.
18. Palmerini T, Dangas G, Mehran R, et al. Predictors and implications of stent thrombosis in non-ST-segment elevation acute coronary syndromes: The ACUITY Trial. Circ Cardiovasc Interv 2011;4:577–584.
19. D'Ascenzo F, Bollati M, Clementi F, et al. Incidence and predictors of coronary stent thrombosis: Evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. Int J Cardiol 2013;167:575–584.
20. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 2007;369:667–678.
21. Mehran R, Baber U, Steg PG, et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 2013;382:1714–1722.
22. Palmerini T, Caixeta A, Genereux P, et al. Comparison of clinical and angiographic prognostic risk scores in patients with acute coronary syndromes: Analysis from the Acute Catheterization and Urgent Intervention Triage StrategY (ACUITY) trial. Am Heart J 2012;163:383–391, 391. e381–385.
23. Généreux P, Madhavan MV, Mintz GS, et al. Ischemic outcomes after coronary intervention of calcified vessels in acute coronary syndromes. Pooled analysis from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) and ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) TRIALS. J Am Coll Cardiol 2014;63:1845–1854.
24. Yadav M, Genereux P, Palmerini T, et al. SYNTAX score and the risk of stent thrombosis after percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: An ACUITY trial substudy. Catheter Cardiovasc Interv 2015;85:1–10.
25. Farooq V, Serruys PW, Zhang Y, et al. Short-Term and Long-Term Clinical Impact of Stent Thrombosis and Graft Occlusion in the SYNTAX Trial at 5 Years: Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery Trial. J Am Coll Cardiol 2013;62:2360–2369.
26. Généreux P, Rutledge DR, Palmerini T, et al. Stent thrombosis and dual antiplatelet therapy interruption with everolimus-eluting stents: Insights from the Xience V coronary stent system trials. Circ Cardiovasc Interv 2015;8:e001362
27. Kotsia A, Brilakis ES, Held C, et al. Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2014;168:68–75 e62.
28. Palmerini T, Calabro P, Piscione F, et al. Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: The GEPRESS study. JACC Cardiovasc Interv 2014;7:1117–1127.
29. Brodie BR, Garg A, Stuckey TD, et al. Fixed and Modifiable Correlates of Drug-Eluting Stent Thrombosis From a Large All-Comers Registry: Insights From ADAPT-DES. Circ Cardiovasc Interv 2015;8:e002568
30. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045–1057.
31. Wiviott SD, Braunwald E, McCabe CH, et al., Investigators T-T. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001–2015.
32. Abdel-Wahab M, Richardt G, Joachim Buttner H, et al. High-speed rotational atherectomy before paclitaxel-eluting stent implantation in complex calcified coronary lesions: The randomized ROTAXUS (Rotational Atherectomy Prior to Taxus Stent Treatment for Complex Native Coronary Artery Disease) trial. JACC Cardiovasc Interv 2013;6:10–19.
33. Chambers JW, Feldman RL, Himmelstein SI, et al. Pivotal trial to evaluate the safety and efficacy of the orbital atherectomy system in treating de novo, severely calcified coronary lesions (ORBIT II). JACC Cardiovasc Interv 2014;7:510–518.
34. Jang JS, Song YJ, Kang W, et al. Intravascular ultrasound-guided implantation of drug-eluting stents to improve outcome: A meta-analysis. JACC Cardiovasc Interv 2014;7:233–243.
35. Witzenbichler B, Maehara A, Weisz G, et al. Relationship between intravascular ultrasound guidance and clinical outcomes after drug-eluting stents: The assessment of dual antiplatelet therapy with drug-eluting stents (ADAPT-DES) study. Circulation 2014;129:463–470.
36. Feres F, Costa RA, Abizaid A, et al., Investigators OT. Three vs. twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: The OPTIMIZE randomized trial. Jama 2013;310:2510–2522.
37. Valgimigli M, Campo G, Monti M, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: A randomized multicenter trial. Circulation 2012;125:2015–2026.
38. Silber S, Kirtane AJ, Belardi JA, et al. Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. Eur Heart J 2014;35:1949–1956.
39. Gilard M, Barragan P, Noryani AA, et al. 6 versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: The randomized, multicenter ITALIC trial. J Am Coll Cardiol 2015;65:777–786.
40. Mauri L, Kereiakes DJ, Yeh RW, et al., Investigators DS. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371:2155–2166.
41. Généreux P, Stone GW, Harrington RA, et al, Investigators CP. Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: Insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). J Am Coll Cardiol 2014;63:619–629.